Smithkline Beecham Corporation

Glaxosmithkline LLC

Other

University of Vermont and State Agricultural College

Mitchell Stuart Gross

Stephen Dudley Holmes

Edward Robert Appelbaum

Robert S Ames

Irwin M Chaiken

Richard M Cook

Timothy Wayne Theisen

Lynette Jane McMillan

Daniel Robert Sylvester

Kristine Kay Kikly

Nabil A Elshourbagy

Eduardo Agustin Padlan

Mark Robert Hurle

Giora Zeev Feuerstein

William Robert Church

Paul G Lysko

Andrew John Nichols

Michael Neal Blackburn

John Adamou

Arunbhai Haribhai Patel

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.

Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders

Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Anti-factor IX/IXa antibodies

Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control of embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility. Antagonists against such REQUIEM and their use as a therapeutic to treat Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS, ALS, cererbellar degeneration, ischemic injury, myocardial infarction, AIDS, myelodysplastic syndromes, aplastic anemia, male pattern baldness, and head injury damage are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding REQUIEM polypeptide and for detecting altered levels of the polypeptide in a host.

Human requiem

Human Marco scavenger receptor polypeptides (HMarcoSR) and DNA (RNA) encoding such HMarcoSR and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such HMarcoSR for the treatment of various cardivascular disorders, gangrene, and loss of function in the extremeties. Antagonists against such HMarcoSR and their use as a therapeutic to treat of various cardivascular disorders, gangrene, and loss of function in the extremeties are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the HMarcoSR and for detecting altered levels of the polypeptide in a host.

Human marco scavenger receptor

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated

Nucleic acids encoding immunoglobulin domains

Chimeric and humanized IL4 MAbs derived from high affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.

DNA encoding recombinant IL4 antibodies useful in treatment of IL4

Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility. Antagonists against such REQUIEM and their use as a therapeutic to treat Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS, ALS, cererbellar degeneration, ischemic injury, myocardial infarction, AIDS, myelodysplastic syndromes, aplastic anemia, male pattern baldness, and head injury damage are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding REQUIEM polypeptide and for detecting altered levels of the polypeptide in a host.

Human Marco scavenger receptor polypeptides (HMarcoSR) and DNA (RNA) encoding such HMarcoSR and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such HMarcoSR for the treatment of various cardivascular disorders, gangrene, and loss of fuunction in the extremeties. Antagonists against such HMarcoSR and their use as a therapeutic to treat various cardivascular disorders, gangrene, and loss of fuunction in the extremeties are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the HMarcoSR and for detecting altered levels of the polypeptide in a host.

Growing community of inventors

Wayne, PA, United States of America

Mitchell Stuart Gross